Premium
Tumour markers with clinically controlled cut‐offs for suspected cancer
Author(s) -
Bosch Xavier,
Molina Rafael,
Marrades Ramon,
Augé Josep M.,
Pellicé Martina,
LópezSoto Alfonso
Publication year - 2021
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/eci.13523
Subject(s) - medicine , carcinoembryonic antigen , cancer , enolase , receiver operating characteristic , confidence interval , prostate cancer , oncology , lung cancer , oncofetal antigen , stage (stratigraphy) , antigen , gastroenterology , pathology , immunology , immunohistochemistry , tumor associated antigen , immunotherapy , paleontology , biology
Background Due to insufficient scientific evidence, panels of tumour markers (TMs) are currently not recommended for use in suspected cancer. However, recent well‐designed studies have revealed a potential clinical value in lung cancer. We analysed the diagnostic accuracy of a panel of 11 circulating TMs with clinically controlled thresholds in the differentiation of cancer from nonmalignant diseases. Methods We prospectively recruited 4776 consecutive patients presenting with focal or nonspecific symptoms suggestive of cancer who underwent testing for 11 serum TMs before diagnosis was known. The study abided by 2015 STARD guidelines. Tumour markers included, among others, carbohydrate antigen 19‐9, carcinoembryonic antigen, alpha‐fetoprotein, squamous cell carcinoma‐associated antigen, prostate‐specific antigen (males), neuron‐specific enolase, progastrin‐releasing peptide and carbohydrate antigen 125. Thresholds were adjusted for the presence of kidney failure, liver disease, effusions and dermatological disorders. Results showing ≥1 TMs with concentrations above threshold were considered positive. Results Benign diseases were diagnosed in 3281 (68.7%) patients and cancer in 1495 (31.3%), with epithelial cancers in 1214 (77% at stage IV). When applying criteria for controlled thresholds, overall specificity was 98%. Overall sensitivity of the panel in epithelial cancers was 72.2%, positive predictive value 93% and negative predictive value 90.5%. The area under the receiver operating characteristic curve was 0.920 (95% confidence interval, 0.902‐0.924). Conclusions By using clinically controlled cut‐offs, the combined panel demonstrated an excellent ability to discriminate epithelial cancers from nonmalignant diseases. However, its use in clinical practice would need formal validation through a multicentre controlled trial assessing a panel‐guided strategy vs. standard diagnosis.